XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 165.2 $ 258.4
Marketable investment securities 103.2 81.4
Trade accounts receivable 101.7 91.3
Inventory 15.6 15.3
Prepaid taxes 18.8 18.4
Prepaid expenses and other current assets 22.9 20.0
Total current assets 427.4 484.8
Operating lease right-of-use assets 70.9 81.8
Long-term marketable investment securities 70.8 59.0
Property, plant, and equipment, net 45.7 43.5
Intangibles, net 393.6 404.1
Goodwill 238.8 239.2
Other assets 8.2 8.3
Total assets 1,255.4 1,320.7
Current liabilities:    
Accounts payable 27.1 29.6
Accrued liabilities 124.8 156.5
Current maturities of operating lease liabilities 13.4 13.0
Deferred revenues 0.7 5.2
Total current liabilities 166.0 204.3
Unrecognized tax benefits 28.0 27.9
Long-term deferred taxes 29.9 35.8
Noncurrent operating lease liabilities 76.5 79.3
Other long-term liabilities 4.9 5.6
Total liabilities 305.3 352.9
Commitments and contingencies
Stockholders’ equity:    
Common stock, 80.3 million and 80.0 million shares outstanding at March 31, 2022 and December 31, 2021, respectively 0.8 0.8
Additional paid-in capital 1,231.6 1,226.3
Accumulated other comprehensive loss (7.6) (5.1)
Accumulated deficit (274.7) (254.2)
Total Myriad Genetics, Inc. stockholders’ equity 950.1 967.8
Non-controlling interest 0.0 0.0
Total stockholders' equity 950.1 967.8
Total liabilities and stockholders’ equity $ 1,255.4 $ 1,320.7